𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Local excision with adjuvant imatinib therapy for anorectal gastrointestinal stromal tumors

✍ Scribed by Centonze, D.; Pulvirenti, E.; Pulvirenti D’Urso, A.; Franco, S.; Cinardi, N.; Giannone, G.

Book ID
125352843
Publisher
Springer
Year
2013
Tongue
English
Weight
356 KB
Volume
17
Category
Article
ISSN
1123-6337

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Imatinib as adjuvant therapy for gastroi
Imatinib as adjuvant therapy for gastrointestinal stromal tumors: a systematic review
✍ Munira Essat; Katy Cooper 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 French ⚖ 266 KB 👁 1 views

## Abstract The high risk of recurrence in resected gastrointestinal stromal tumor (GIST) highlights the need for effective adjuvant treatment. This review evaluates the clinical efficacy and safety of imatinib for adjuvant treatment of localized KIT (CD117)‐positive resected GIST. Relevant studies

Systemic therapy for advanced gastrointe
Systemic therapy for advanced gastrointestinal stromal tumors: Beyond imatinib
✍ Edward J. Kim; Mark M. Zalupski 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 88 KB

## Abstract Progression on first‐line therapy with imatinib in gastrointestinal stromal tumors (GIST) is caused by either initial resistance or more often a secondary mutation in tyrosine kinases KIT or PDGFR. Therapies in development for imatinib‐resistant GIST include agents that target KIT/PDGFR